Nitroprusside CRI

Direct nitric oxide donor. Releases NO spontaneously in plasma, activating guanylate cyclase in vascular smooth muscle → cGMP → vasodilation. Mixed arterial AND venous vasodilator (unlike pure arteriodilators such as hydralazine), so reduces both preload and afterload, the property that makes SNP useful for refractory CHF. Onset 30 seconds to 1 minute IV; offset 1–2 minutes after stop, making it among the most titratable IV drugs available. Metabolized in erythrocytes to cyanide ions, then in liver to thiocyanate; thiocyanate eliminated renally. Cyanide accumulation is the principal toxicity risk; thiocyanate accumulation matters specifically in renal failure.

Open calculator →

Clinical background

Nitroprusside is a direct nitric-oxide donor that produces balanced arterial and venous vasodilation. It is the most potent and most titratable vasodilator available in vet ICU practice. The clinical pivot is the speed of onset and offset: effect appears within 30 seconds of starting the infusion and disappears within 1–2 minutes of stopping, which makes it the right drug when hemodynamics need to be moved quickly and the response needs to be reversible just as fast. The trade-offs are the patient-safety surface (light sensitivity, cyanide accumulation, the requirement for continuous BP monitoring) and the preparation discipline that nitroprusside demands more than any other CRI drug in the catalog.

Pharmacology

Nitroprusside is a sodium-iron-cyanide complex that releases nitric oxide non-enzymatically on contact with sulfhydryl groups in vascular smooth muscle. NO activates guanylyl cyclase, raises intracellular cGMP, and produces smooth-muscle relaxation. The action profile is:

• Arteriolar dilation, reducing systemic vascular resistance and afterload
• Venous dilation, reducing venous return and preload
• The afterload and preload effects are roughly balanced, which distinguishes nitroprusside from hydralazine (predominantly arteriolar) and nitroglycerin (predominantly venous at low doses)
• No direct cardiac effect: contractility and rate do not change from the drug itself. Reflex tachycardia frequently appears when MAP drops, mediated by baroreceptor activation

Onset is within 30–60 seconds of starting the IV infusion. The effect dissipates within 1–2 minutes after the infusion stops. The molecule is metabolized to cyanide and then to thiocyanate via the rhodanese pathway in the liver. Cyanide is acutely toxic; thiocyanate accumulates with prolonged infusion or in renal dysfunction and is the source of the chronic toxicity concern.

Indications

Primary use cases:

• Hypertensive emergency, defined for vet purposes as MAP > 140 mmHg with active end-organ injury (acute kidney injury, encephalopathy, retinal hemorrhage). Pheochromocytoma management after α-blockade, severe hypertension in catecholamine excess, post-cardiac-surgery hypertension, and rarely idiopathic systemic hypertension that is decompensating. Nitroprusside is the drug to reach for when MAP needs to come down promptly and the response needs to be titratable in real time.
• Acute decompensated heart failure with pulmonary edema refractory to diuresis. In MMVD stage D dogs and end-stage DCM, the combination of nitroprusside and dobutamine (afterload reduction plus inotropic support) can produce dramatic improvement when standard therapy has stalled. Typical duration of use is 12–48 hours, after which oral vasodilators (pimobendan, oral hydralazine, ACE inhibitors) take over.
• Mitral regurgitation severe enough to compromise forward flow. Reducing afterload preferentially reduces regurgitant fraction more than forward stroke volume, improving systemic perfusion.
• Cardiogenic shock with adequate filling pressures and acceptable MAP. Less common indication, used to maximize forward flow when the heart is failing but BP is not yet collapsed.

Nitroprusside is not for chronic outpatient use. The half-life is far too short, the preparation discipline too demanding, and the toxicity profile too risky for any but the inpatient ICU setting.

Dosing

• Dogs and cats, hypertension or heart failure CRI: 0.5–10 µg/kg/min, titrated against MAP and clinical response.
• Initial rate: 0.5–1 µg/kg/min.
• Caution above: 8 µg/kg/min. Cyanide accumulation becomes more likely above this threshold, especially in patients with reduced hepatic function (rhodanese pathway) or impaired thiosulfate availability.
• Hard maximum: 10 µg/kg/min in most references. Doses above this are reported but should prompt reconsideration of indication and addition of alternative agents.
• No loading dose. Nitroprusside is pure titration. The starting rate is the maintenance rate; adjust upward in small increments while watching MAP.

Titrate in 0.5 µg/kg/min increments every 3–5 minutes against the MAP target. The target depends on the indication: for hypertensive emergency, drop MAP by no more than 25% in the first hour, then to a target ~120–140 mmHg over 2–6 hours. For heart-failure use, target the MAP that maintains acceptable systemic perfusion (typically 70–100 mmHg) without overshooting into hypotension.

Cat dosing uses the same range as dogs. Cats are smaller patients per kg and the per-mL math means small pump-rate errors produce proportionally larger MAP swings; the dilute concentration tier (100 µg/mL) is appropriate for cats and small dogs.

Administration

This is the section that matters most. Nitroprusside is unforgiving of preparation errors.

Stock comes as a 50 mg lyophilized powder vial, reconstituted with 2–3 mL of 5% dextrose to produce a 25 mg/mL stock. The stock is then diluted into 5% dextrose at the working concentration. The InfusionFox calculator preselects three weight-banded preparations (500, 200, or 100 µg/mL).

Strict requirements:

• 5% dextrose only as the diluent. Nitroprusside is unstable in sodium-chloride-containing fluids and degrades faster. Do not use 0.9% NaCl or lactated Ringer’s.
• Light protection. The bag and the entire IV line must be wrapped in foil or opaque material from the moment the drug is reconstituted. Light exposure degrades nitroprusside to free cyanide within hours. Discard immediately if the bag’s color changes from pale brown to blue, green, or red.
• Opaque or amber-tinted IV tubing, where available. If not available, foil wrap the standard tubing.
• Discard within 24 hours of reconstitution regardless of how the bag looks.
• Continuous direct BP monitoring, ideally an arterial line. Oscillometric is acceptable in the short term but lacks the resolution and continuity that titrating against a sub-2-minute-half-life vasodilator demands. The minimum is BP every 5 minutes; the standard is continuous.

Y-site compatibility is broad with most other vasoactive drugs (norepinephrine, dobutamine, esmolol, magnesium). Do not co-administer in the same line with drugs that change pH significantly (sodium bicarbonate) or known incompatibles.

Drug interactions

• Other vasodilators (hydralazine, nitroglycerin, ACE inhibitors) have additive hypotensive effects. The combination is sometimes deliberate in refractory heart failure but warrants closer BP monitoring.
• Sildenafil and other PDE5 inhibitors have synergistic cGMP-mediated vasodilation. Combination can produce severe hypotension; check medication history before starting.
• Inhalant anesthetics produce additive hypotension; reduce inhalant concentration when adding nitroprusside to a maintenance plan during anesthesia.
• Beta-blockers can blunt the reflex tachycardia that accompanies nitroprusside-induced MAP drop. This is sometimes desirable (reducing the rate response in patients with arrhythmia or heart failure) but can also limit the patient’s compensatory capacity if MAP drops further than intended.

Adverse effects

Two distinct categories: hemodynamic (acute, dose-related) and toxic (cumulative, related to cyanide and thiocyanate).

Hemodynamic:

• Hypotension: the most common immediate adverse effect, particularly with abrupt dose increases or in volume-depleted patients
• Reflex tachycardia: baroreceptor-driven, expected at typical doses, usually well tolerated
• Coronary steal: redistribution of coronary flow away from ischemic zones via dilation of non-ischemic vessels; reported in human medicine, clinically relevant in patients with known coronary disease (rare in vet ICU)

Toxic:

• Cyanide toxicity: tachypnea, metabolic acidosis with elevated lactate, narrowed venous-arterial oxygen difference, mental status change. More likely above 8 µg/kg/min, with prolonged infusion (>24–48 hours), and with hepatic dysfunction (reduced rhodanese activity). Severe cases require sodium thiosulfate (150–200 mg/kg IV) and hydroxocobalamin or sodium nitrite. The earliest warning sign is rising lactate despite improving MAP, which can be misread as worsening shock.
• Thiocyanate accumulation: nausea, fatigue, confusion, peripheral neuropathy at very high serum levels. Develops with prolonged infusion (>72 hours) or in renal dysfunction where clearance is impaired. Less acutely dangerous than cyanide but limits chronic use.
• Methemoglobinemia: rare at therapeutic doses; can develop with extended high-dose infusion. Cyanosis with normal pulse oximetry and chocolate-brown blood are the bedside signs.

Monitoring

• Continuous BP by arterial line is the standard; oscillometric every 5 minutes is the minimum acceptable. MAP-targeted titration is the workflow.
• Continuous ECG for rate and rhythm.
• Lactate trend. Rising lactate during nitroprusside infusion has three possible explanations: hypoperfusion from over-dilation, cyanide accumulation, or worsening of the underlying shock. The first is excluded by checking BP, the second is the differential consideration. Persistent unexplained lactate elevation in a patient on nitroprusside is cyanide toxicity until proven otherwise.
• Venous blood gas: narrowing of the venous-arterial O₂ difference (venous O₂ rising toward arterial) is the classic sign of cyanide-mediated cytochrome oxidase inhibition. Cells cannot extract O₂, so venous blood looks arterial.
• Mental status as a perfusion and toxicity marker.
• Urine output as a perfusion marker.
• Renal function (BUN, creatinine) at intervals during prolonged infusion, given thiocyanate accumulation in renal dysfunction.
• The infusion bag and tubing for color change (pale brown is normal; blue, green, red, or any darkening is degradation, discard the bag).
• Direct infusion site inspection; extravasation is less of a tissue-toxicity concern than with catecholamines but the catheter integrity matters for delivery accuracy.

Weaning

Reduce in 0.5 µg/kg/min increments every 10–15 minutes against MAP. Abrupt cessation can produce rebound hypertension, particularly after prolonged infusion (>12 hours), through wind-up of the renin-angiotensin axis during the infusion. Transition to oral antihypertensive therapy (amlodipine, ACE inhibitor) before stopping the infusion in patients who will continue to need afterload reduction.

For heart-failure use, transition to oral pimobendan, ACE inhibitor, and oral hydralazine (where appropriate) before stopping the infusion. The standard is 24–48 hours of nitroprusside followed by oral conversion.

Sources

• Plumb’s Veterinary Drugs, nitroprusside monograph (current edition).
• Côté E, Edwards NJ, Ettinger SJ, et al. Management of congestive heart failure. In: Ettinger SJ, Feldman EC, Côté E, eds. Textbook of Veterinary Internal Medicine. 8th ed. Elsevier; 2017. (Nitroprusside use in stage D refractory CHF.)
• Acierno MJ, Brown S, Coleman AE, et al. ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2018;32(6):1803–1822. (Vet hypertensive emergency management and nitroprusside place in the algorithm.)
• Hopper K, ed. Small Animal Critical Care Medicine. 3rd ed. Elsevier; 2023. (Acute decompensated heart failure ICU management.)